Candidates: Monoclonal antibodies against the coronavirus SARS CoV 2
Type: Fully human monoclonal antibodies using HBM’s H2L2 Harbour Mice® platform.
Status: Mount Sinai and Harbour BioMed said March 6 they entered into a multi-year, multifaceted collaboration thorugh which Mount Sinai researchers will use HBM’s H2L2 Harbour Mice platform to generate monoclonal antibodies against SARS-CoV-2 as well as develop novel, fully human antibodies to prevent and treat diseases in areas that include oncology and immunology.
Mount Sinai is also developing an antibody test for which the healthcare system’s Mount Sinai Laboratory (MSL), Center for Clinical Laboratories in April received FDA Emergency Use Authorization. The test is designed to detect the presence or absence of antibodies to SARS-CoV-2—and may also be used to identify positive specimens with an antibody titer (level) up to a dilution of 1:2880 for the identification of individuals with higher antibody titers.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: